VISTA

Byaibio

VISTA is an immune checkpoint protein and immune regulation target that helps suppress T cell activation, making it relevant to tumor immune evasion and immunotherapy response prediction. It has been explored as an imaging target for assessing tumor immune status, especially through PET tracers based on the cyclic peptide antagonist scaffold AP1049 and its derivatives ap1049, 68ga-ga-ap1049, 68ga-ga-ahx-ap1049, and 68ga-ga-pip-ap1049. In cancers, VISTA-targeted PET imaging has been developed with cyclic peptide-based radiotracers to visualize checkpoint expression noninvasively (PMID:41978961). In ovarian cancer, platelet-driven upregulation of vista contributes to an immunosuppressive tumor microenvironment, and elevated VISTA levels were associated with poorer clinical outcomes (PMID:41841642). Overall, the literature highlights VISTA as both a mechanistic immune checkpoint and a practical biomarker/imaging target for cancer immunology.

Cancer

  • Cyclic peptide-based PET tracers were developed to target vista for immune checkpoint imaging in cancers, supporting noninvasive assessment of tumor immune status. (PMID:41978961)
  • The tracer program used the cyclic peptide antagonist scaffold ap1049 and included 68ga-ga-ap1049, 68ga-ga-ahx-ap1049, and 68ga-ga-pip-ap1049 as VISTA-targeted radiotracers. (PMID:41978961)
  • vista was described as an immune checkpoint protein targeted for PET imaging in cancer settings. (PMID:41978961)
  • In ovarian cancer models, platelets induced/upregulated vista, linking it to an immunosuppressive tumor microenvironment. (PMID:41841642)
  • Elevated vista levels were associated with poorer clinical outcomes in ovarian cancer. (PMID:41841642)